Yarrow Bioscience (YARW) Income from Continuing Operations (2017 - 2026)
Yarrow Bioscience's (YARW) quarterly Income from Continuing Operations came in at 3585000.0 in Q1 2026, up 58.33% YoY from 2264279.79 in Q1 2025, and up 37.62% on a QoQ basis from 5747000.0 in Q2 2025.
Yarrow Bioscience (YARW) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 10 years of Income from Continuing Operations data on file, last reported at 3585000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 58.33% year-over-year to 3585000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 29949000.0 (up 28.98% YoY) and the FY2025 annual result came in at 26736000.0, up 32.84% from the prior year.
- Income from Continuing Operations climbed to 3585000.0 in Q1 2026, from 5747000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 3585000.0 in Q1 2026 to a low of 12157000.0 in Q3 2024.
- A 5-year average of 7970666.67 and a median of 8235000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations tumbled 100.25% — and 2026, when it jumped 58.33%.
- Tracing YARW's Income from Continuing Operations over 5 years: stood at 7761000.0 in 2022, then gained by 20.73% to 6152000.0 in 2023, then slumped by 95.29% to 12014000.0 in 2024, then jumped by 52.16% to 5747000.0 in 2025, then soared by 37.62% to 3585000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 3585000.0 (Q1 2026), 5747000.0 (Q2 2025), and 8603000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Yarrow Bioscience | 31.25 Mn | 8.33 Mn | - | -2.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.90 Mn |
| Mar 31, 2026 | -3.59 Mn |
| Jun 30, 2025 | -5.75 Mn |
| Mar 31, 2025 | -8.60 Mn |
| Dec 31, 2024 | -12.01 Mn |
| Sep 30, 2024 | -12.16 Mn |
| Jun 30, 2024 | -9.40 Mn |
| Mar 31, 2024 | -6.24 Mn |
| Dec 31, 2023 | -6.15 Mn |
| Sep 30, 2023 | -6.07 Mn |
| Jun 30, 2023 | -10.04 Mn |
| Mar 31, 2023 | -5.61 Mn |
| Dec 31, 2022 | -7.76 Mn |
| Sep 30, 2022 | -9.26 Mn |
| Jun 30, 2022 | -8.24 Mn |
| Mar 31, 2022 | -8.69 Mn |
| Dec 31, 2021 | -8.37 Mn |
| Sep 30, 2021 | -14.28 Mn |
| Jun 30, 2021 | -10.69 Mn |
| Mar 31, 2021 | -10.88 Mn |